2022 January 10
1.
The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Liu L, Li J, Ke Y, Zeng X, Gao J, Ba X, Wang R.
Cell Mol Life Sci. 2022 Jan 9;79(1):60. doi: 10.1007/s00018-021-04109-w.
PMID: 35000037 Review.
2.
HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis. Montini F, Colombo B, Giordano A, Lopez ID, Moiola L, Martinelli V, Filippi M.
Neurol Sci. 2022 Jan 9. doi: 10.1007/s10072-021-05803-0. Online ahead of print.
PMID: 35000014 No abstract available.
3.
Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms. Cruz RA, Varkey T, Flavia A, Samways APA, Garza A, Greenlee G, Friess M, Sconzert J, Aijaz A, Arruda W, Khouri J, Ellington K, Frohman TC, Frohman EM.
J Neurol. 2022 Jan 9. doi: 10.1007/s00415-021-10915-w. Online ahead of print.
PMID: 34999960
4.
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents. Korsen M, Pfeuffer S, Rolfes L, Meuth SG, Hartung HP.
J Neurol. 2022 Jan 9. doi: 10.1007/s00415-021-10956-1. Online ahead of print.
PMID: 34999925
5.
Abnormal activation of yap/Taz contributes to the pathogenesis of tuberous sclerosis complex. Terry BK, Park R, Cho SH, Crino PB, Kim S.
Hum Mol Genet. 2022 Jan 6:ddab374. doi: 10.1093/hmg/ddab374. Online ahead of print.
PMID: 34999833
6.
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors. Etemadifar M, Salari M, Esnaashari A, Ghazanfaripoor F, Sayahi F, Akhavan Sigari A, Sedaghat N.
Mult Scler Relat Disord. 2022 Jan 2;58:103488. doi: 10.1016/j.msard.2022.103488. Online ahead of print.
PMID: 34999375
7.
Cerebellar contributions to motor and cognitive control in Multiple Sclerosis. Fritz NE, Edwards EM, Ye C, Prince J, Yang Z, Gressett T, Keller J, Myers E, Calabresi PA, Zackowski KM.
Arch Phys Med Rehabil. 2022 Jan 5:S0003-9993(21)01773-1. doi: 10.1016/j.apmr.2021.12.010. Online ahead of print.
PMID: 34998712
2022 January 09
1.
Sarcopenia in patients with multiple sclerosis. Yuksel H, Balaban M, Tan OO, Mungan S.
Mult Scler Relat Disord. 2021 Dec 26;58:103471. doi: 10.1016/j.msard.2021.103471. Online ahead of print.
PMID: 34998245
2.
Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults. Abboud H, Briggs F, Buerki R, Elkasaby M, BacaVaca GF, Fotedar N, Geiger C, Griggins C, Lee C, Lewis A, Serra A, Shrestha R, Winegardner J, Shaikh A.
J Neurol Sci. 2021 Dec 31;434:120124. doi: 10.1016/j.jns.2021.120124. Online ahead of print.
PMID: 34998237
3.
Dairy Intake and Parkinson’s Disease: A Mendelian Randomization Study. Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, Grover S, Mohamed O, Portugal B, May P, Bobbili DR, Radivojkov-Blagojevic M, Lichtner P, Singleton AB, Hernandez DG, Edsall C, Mellick GD, Zimprich A, Pirker W, Rogaeva E, Lang AE, Koks S, Taba P, Lesage S, Brice A, Corvol JC, Chartier-Harlin MC, Mutez E, Brockmann K, Deutschländer AB, Hadjigeorgiou GM, Dardiotis E, Stefanis L, Simitsi AM, Valente EM, Petrucci S, Duga S, Straniero L, Zecchinelli A, Pezzoli G, Brighina L, Ferrarese C, Annesi G, Quattrone A, Gagliardi M, Matsuo H, Kawamura Y, Hattori N, Nishioka K, Chung SJ, Kim YJ, Kolber P, van de Warrenburg BPC, Bloem BR, Aasly J, Toft M, Pihlstrøm L, Correia Guedes L, Ferreira JJ, Bardien S, Carr J, Tolosa E, Ezquerra M, Pastor P, Diez-Fairen M, Wirdefeldt K, Pedersen NL, Ran C, Belin AC, Puschmann A, Hellberg C, Clarke CE, Morrison KE, Tan M, Krainc D, Burbulla LF, Farrer MJ, Krüger R, Gasser T, Sharma M, Elbaz A; Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease (Courage-PD) Consortium.
Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902. Online ahead of print.
PMID: 34997937
4.
Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach. Piena MA, Kroep S, Simons C, Fenwick E, Harty GT, Wong SL, van Hout BA.
Adv Ther. 2022 Jan 8. doi: 10.1007/s12325-021-02032-x. Online ahead of print.
PMID: 34997918 No abstract available.
5.
Genes, brain dynamics and art: the genetic underpinnings of creativity in dancing, musicality and visual arts. Sotiropoulos MG, Anagnostouli M.
J Integr Neurosci. 2021 Dec 30;20(4):1095-1104. doi: 10.31083/j.jin2004110.
PMID: 34997732
6.
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. Chung WP, Huang WL, Liao WA, Hung CH, Chiang CW, Cheung CHA, Su WC.
Sci Rep. 2022 Jan 7;12(1):241. doi: 10.1038/s41598-021-04328-y.
PMID: 34997132
7.
The effects of transcranial direct current stimulation on sleep in patients with multiple sclerosis-A pilot study. Chalah MA, Grigorescu C, Kümpfel T, Lefaucheur JP, Padberg F, Palm U, Ayache SS.
Neurophysiol Clin. 2022 Jan 4:S0987-7053(21)00127-1. doi: 10.1016/j.neucli.2021.12.001. Online ahead of print.
PMID: 34996695
2022 January 08
1.
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO. van Kempen ZL, Hogenboom L, Killestein J.
Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441. Online ahead of print.
PMID: 34994665 No abstract available.
2.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL.
Mult Scler. 2022 Jan 7:13524585211061861. doi: 10.1177/13524585211061861. Online ahead of print.
PMID: 34994579
3.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X.
Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343. Online ahead of print.
PMID: 34994577
4.
Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care. Khanna A, Jones GB.
Front Digit Health. 2021 Dec 21;3:803315. doi: 10.3389/fdgth.2021.803315. eCollection 2021.
PMID: 34993505 Free PMC article.
5.
Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, Airas L.
Brain Commun. 2021 Dec 22;4(1):fcab301. doi: 10.1093/braincomms/fcab301. eCollection 2022 Feb.
PMID: 34993478 Free PMC article.
6.
Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab. Rosenkranz SC, Häußler V, Kolster M, Willing A, Matschke J, Röcken C, Stürner K, Leypoldt F, Tolosa E, Friese MA.
Brain Commun. 2021 Dec 16;4(1):fcab292. doi: 10.1093/braincomms/fcab292. eCollection 2022 Feb.
PMID: 34993476 Free PMC article.
7.
Diagnostic features of tuberous sclerosis complex: case report and literature review. Alshoabi SA, Hamid AM, Alhazmi FH, Qurashi AA, Abdulaal OM, Aloufi KM, Daqqaq TS.
Quant Imaging Med Surg. 2022 Jan;12(1):846-861. doi: 10.21037/qims-21-412.
PMID: 34993123 Free PMC article.
8.
Prevalence of Anxiety and Depression in Patients With Multiple Sclerosis in Saudi Arabia: A Cross-Sectional Study. Aljishi RH, Almatrafi RJ, Alzayer ZA, Alkhamis BA, Yaseen EE, Alkhotani AM.
Cureus. 2021 Dec 29;13(12):e20792. doi: 10.7759/cureus.20792. eCollection 2021 Dec.
PMID: 34993046 Free PMC article.
9.
Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study. Dal-Bianco A, Schranzer R, Grabner G, Lanzinger M, Kolbrink S, Pusswald G, Altmann P, Ponleitner M, Weber M, Kornek B, Zebenholzer K, Schmied C, Berger T, Lassmann H, Trattnig S, Hametner S, Leutmezer F, Rommer P.
Front Neurol. 2021 Dec 21;12:632749. doi: 10.3389/fneur.2021.632749. eCollection 2021.
PMID: 34992573 Free PMC article.
10.
Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. Hernandez Fustes OJ, Kay CSK, Lorenzoni PJ, Ducci RD, Werneck LC, Scola RH.
J Cent Nerv Syst Dis. 2021 Dec 21;13:11795735211057315. doi: 10.1177/11795735211057315. eCollection 2021.
PMID: 34992486 Free PMC article.
11.
Divergent time-varying connectivity of thalamic sub-regions characterizes clinical phenotypes and cognitive status in multiple sclerosis. Carotenuto A, Valsasina P, Hidalgo de la Cruz M, Cacciaguerra L, Preziosa P, Marchesi O, Filippi M, Rocca MA.
Mol Psychiatry. 2022 Jan 7. doi: 10.1038/s41380-021-01401-w. Online ahead of print.
PMID: 34992237
12.
Facial myokymia as the presenting feature of multiple sclerosis. Parr AC, Bashford J, Silber E.
Pract Neurol. 2022 Jan 6:practneurol-2021-003268. doi: 10.1136/practneurol-2021-003268. Online ahead of print.
PMID: 34992095 No abstract available.
2022 January 07
1.
Quantified hemodynamic parameters of the venous system in multiple sclerosis: A systematic review. Bateman AR, Lechner-Scott J, Barber T, Bateman GA, Ramadan S.
Mult Scler Relat Disord. 2021 Dec 29;57:103477. doi: 10.1016/j.msard.2021.103477. Online ahead of print.
PMID: 34990911 Review.
2.
Higher Levels of IgG3 Antibodies in Serum, But Not in CSF, Distinguish Multiple Sclerosis From Other Neurological Disorders. Kennedy PGE, Graner MW, Fringuello A, Zhou W, Pointon T, Alquatli K, Bisel S, Langford D, Yu X.
J Neuroimmune Pharmacol. 2022 Jan 6. doi: 10.1007/s11481-021-10048-x. Online ahead of print.
PMID: 34989971
3.
Neural correlates of dual-task walking in people with central neurological disorders: a systematic review. Kim H, Fraser S.
J Neurol. 2022 Jan 6. doi: 10.1007/s00415-021-10944-5. Online ahead of print.
PMID: 34989867 Review.
4.
Lipopolysaccharide induced altered signaling pathways in various neurological disorders. Singh S, Sahu K, Singh C, Singh A.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Jan 6. doi: 10.1007/s00210-021-02198-9. Online ahead of print.
PMID: 34989812 Review.
5.
Adaptation and Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) for Use in Iranian Patients. Rezaei S, Saberi A, Hatamian H, Ghayeghran A, Khaksari Z, Mollahosein F.
Acta Neurol Taiwan. 2022 Jan 25;31(1):24-35.
PMID: 34988951
6.
The Effect of Month of Birth on Multiple Sclerosis: A Sase-Control Study in Northeast Iran. Sarmadi M, Nezhad MR, Hasanluyi FA, Najafi F, Tamaddon A, Rahimi S.
Acta Neurol Taiwan. 2022 Jan 25;31(1):7-14.
PMID: 34988949
7.
Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients. Begentas OC, Koc D, Kiris E.
Methods Mol Biol. 2022 Jan 6. doi: 10.1007/7651_2021_453. Online ahead of print.
PMID: 34988943
8.
The Effects of Modified Curcumin Preparations on Glial Morphology in Aging and Neuroinflammation. Ullah F, Gamage R, Sen MK, Gyengesi E.
Neurochem Res. 2022 Jan 6. doi: 10.1007/s11064-021-03499-4. Online ahead of print.
PMID: 34988899 Review.
9.
Masked face recognition in patients with relapsing-remitting multiple sclerosis during the ongoing COVID-19 pandemic. Kuzu Kumcu M, Tezcan Aydemir S, Ölmez B, Durmaz Çelik N, Yücesan C.
Neurol Sci. 2022 Jan 6. doi: 10.1007/s10072-021-05797-9. Online ahead of print.
PMID: 34988718
10.
Clinical heterogeneity in patients with myoclonus associated to COVID-19. Álvarez Bravo G, Sánchez Cirera L, Angerri Nadal M, Ramió I Torrentà L.
Neurol Sci. 2022 Jan 6. doi: 10.1007/s10072-021-05802-1. Online ahead of print.
PMID: 34988717
11.
Diagnostic value of lumbar puncture for the etiological assessment of uveitis: a retrospective cohort of 188 patients. Bernier R, Gavoille A, Chirpaz N, Jamilloux Y, Kodjikian L, Mathis T, Sève P.
Graefes Arch Clin Exp Ophthalmol. 2022 Jan 6. doi: 10.1007/s00417-021-05514-4. Online ahead of print.
PMID: 34988612
12.
Diagnosis of Multiple Sclerosis Disease in Brain Magnetic Resonance Imaging Based on the Harris Hawks Optimization Algorithm. Iswisi AFA, Karan O, Rahebi J.
Biomed Res Int. 2021 Dec 27;2021:3248834. doi: 10.1155/2021/3248834. eCollection 2021.
PMID: 34988224 Free PMC article.
13.
Lack of association between C282Y and H63D polymorphisms in the hemochromatosis gene and risk of multiple sclerosis: A meta-analysis. Starčević Čizmarević N, Ćurko-Cofek B, Barac-Latas V, Peterlin B, Ristić S.
Biomed Rep. 2022 Feb;16(2):12. doi: 10.3892/br.2021.1495. Epub 2021 Dec 17.
PMID: 34987796 Free PMC article.
14.
Transcriptional Analysis of Nuclear-Encoded Mitochondrial Genes in Eight Neurodegenerative Disorders: The Analysis of Seven Diseases in Reference to Friedreich’s Ataxia. Elsadany M, Elghaish RA, Khalil AS, Ahmed AS, Mansour RH, Badr E, Elserafy M.
Front Genet. 2021 Dec 20;12:749792. doi: 10.3389/fgene.2021.749792. eCollection 2021.
PMID: 34987545 Free PMC article.
15.
Characterization of Definitive Regulatory B Cell Subsets by Cell Surface Phenotype, Function and Context. Neu SD, Dittel BN.
Front Immunol. 2021 Dec 20;12:787464. doi: 10.3389/fimmu.2021.787464. eCollection 2021.
PMID: 34987513 Free PMC article. Review.
16.
The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis. Paton KF, Robichon K, Templeton N, Denny L, Al Abadey A, Luo D, Prisinzano TE, La Flamme AC, Kivell BM.
Front Neurol. 2021 Dec 20;12:782190. doi: 10.3389/fneur.2021.782190. eCollection 2021.
PMID: 34987466 Free PMC article.
17.
From Forensics to Clinical Research: Expanding the Variant Calling Pipeline for the Precision ID mtDNA Whole Genome Panel. Cortes-Figueiredo F, Carvalho FS, Fonseca AC, Paul F, Ferro JM, Schönherr S, Weissensteiner H, Morais VA.
Int J Mol Sci. 2021 Nov 6;22(21):12031. doi: 10.3390/ijms222112031.
PMID: 34769461 Free PMC article.
18.
Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. Argyriou AA, Karteri S, Bruna J, Mariotto S, Simo M, Velissaris D, Kalofonou F, Cavaletti G, Ferrari S, Kalofonos HP.
Support Care Cancer. 2022 Feb;30(2):1807-1814. doi: 10.1007/s00520-021-06509-x. Epub 2021 Oct 2.
PMID: 34599664